Home » Bangladesh approves emergency use authorization for Coxing’s new crown vaccine

Bangladesh approves emergency use authorization for Coxing’s new crown vaccine

by admin

Summary

[BangladeshapprovesemergencyuseauthorizationforKexingCovid-19vaccine]Bangladesh has authorized the emergency use of Kexing Covid-19 vaccine, becoming the fifth product approved by the country’s drug regulatory agency. According to the report, the General Administration of Pharmaceuticals stated in a notice on Sunday that Dhaka-based Incepta Vaccine Ltd. will act as a local agent to import the vaccine. (Interface News)

Bloomberg reported on June 6 that Bangladesh has authorized the emergency use of Coxing’s new crown vaccine, becoming the fifth product approved by the country’s drug regulatory agency.

According to the report, the General Administration of Pharmaceuticals stated in a notice on Sunday that Incepta Vaccine Ltd, headquartered in Dhaka, said. Will act as a local agent to import the vaccine.

The World Health Organization approved the emergency use authorization for China’s Kexing Covid-19 vaccine on June 1. According to the report, according to an e-mail statement, the World Health Organization (WHO) has approved the emergency use of Kexing vaccine, stating that it “assures countries, funding providers, procurement agencies and communities that it meets safety, efficiency and manufacturing aspects. International standards”.

(Article Source: Interface News)

(Editor in charge: DF532)

Solemnly declare: The purpose of this information is to spread more information, and it has nothing to do with this stand.

.

See also  The opening of the Tokyo Olympics is imminent, and many delegations have been vaccinated against China's new crown vaccine|vaccine|Japan|new crown vaccine_sina news

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy